Xiaohua Yang

Xiaohua Yang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Archives of Medical Research
Verified
Journal Article
Closed access
YWYanghui Wen
Yanghui Wen
JHJun He
Jun He
XXXiaofeng Xue
Xiaofeng Xue
JQJunyi Qiu
Junyi Qiu
YXYinkai Xu
Yinkai Xu
XYXiaohua Yang
Xiaohua Yang

16 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MHMengkui Han
Mengkui Han
JXJunchi Xu
Junchi Xu
XWXunxun Wu
Xunxun Wu
ZHZhiqing Hu
Zhiqing Hu
XHXiaoyuan Hu
Xiaoyuan Hu
JLJin Li
Jin Li

11 December 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MHMengkui Han
Mengkui Han
JXJunchi Xu
Junchi Xu
XWXunxun Wu
Xunxun Wu
ZHZhiqing Hu
Zhiqing Hu
XHXiaoyuan Hu
Xiaoyuan Hu
JLJin Li
Jin Li
Background and aims: Hepatitis B virus (HBV) causes chronic hepatic infection, leading to various advanced liver diseases. Currently, there is still a lack of effective non-invasive biomarkers for evaluating hepatic inflammation and fibrosis. Circulating microRNAs (miRNAs) serve as key regulators and potential biomarkers in the progression and pathogenesis of HBV-associated progressive liver diseases. Here, we characterized the miRNA profile in chronic hepatitis B (CHB) patients and probed their association with liver inflammation and fibrosis. Approaches and results: We profiled 34 candidate miRNAs in serum from a well-characterized HBV Disease Continuum Cohort, comprising 165 individuals in the discovery set (42 healthy controls, HC; 40 CHB; 42 cirrhosis; 41 hepatocellular carcinomas, HCC) and 143 in an independent testing set. Serum miRNA levels were quantified by qRT-PCR. Supervised clustering and correlation analyses revealed distinct miRNA expression profiles across disease stages. Statistical analyses included logistic regression, and ROC/AUC evaluation with 5-fold cross-validation and external validation. Unsupervised clustering and correlation with histological G/S staging revealed stage-specific miRNA signatures: miR-224-5p, miR-125a-5p, and miR-15a-5p peaked in cirrhosis and strongly correlated with fibrosis stage (miR-224-5p: r = 0.606, p = 1.5E-12), while miR-200a-3p and miR-939-5p were predominantly upregulated in HCC. Critically, miR-224-5p emerged as a robust non-invasive biomarker for cirrhosis, with exceptional diagnostic accuracy (AUC = 0.973 in discovery; 0.906 in external validation), significantly outperforming APRI (0.803) and FIB-4 (0.809), and remained the sole independent predictor in multivariable analysis (p = 0.009). For HCC detection, the miR-200a-3p/AFP combined model achieved outstanding performance (AUC > 0.9), substantially improving upon AFP alone (0.737). Bioinformatic prediction of targets (297 for miR-224-5p; 616 for miR-200a-3p) highlighted associated in cancer- and senescence-related pathways; however, these associations are in silico and require experimental validation. Conclusion: We identify miR-224-5p as a fibroinflammatory activity indicator for early cirrhosis detection and miR-200a-3p as a synergistic enhancer of AFP for non-invasive HCC diagnosis, establishing a dual miRNA signature that spans the HBV disease continuum and addresses critical gaps in current risk stratification. These findings highlight the potential of specific serum miRNAs as non-invasive biomarkers for monitoring disease progression and improving the differential diagnosis during the process of HBV-related liver diseases.